Table 1.

Representative table summarizing the role of DCs in each review section.

Mechanism	DC Role	DC Subsets	Cancer Type	References
Tumorigenesis	Treg expansion, immunosuppression, immune tolerance, tumor progression, metastasis	pDCs, LAMP3+cDCs,	Several cancer types	[19,20]
Immune Surveillance	expansion of tumor-promoting Th17, immune suppression in TME, enhancement/inhibition of immune surveillance	tDCs, BM-DCs, cDC1	Pancreatic cancer, ESCC, T cell lymphomas, Lung cancer	[51,52,53,55]
Immunological memory	Suppression of T cell activation, production of IL-4-producing CD4 Tm cells	Immunoregulatory DCs,	Several cancer types	[57,58,59]
Immunoediting	T-cell priming, epitope spreading	cDC1	Pancreatic adenocarcinoma	[60]
T cell tolerance	Immune T cell tolerance, tolerance-induced apoptosis, tolerance-induced T cell exhaustion	Merocytic DCs, pDCs, ATDCs, CD103+ DCs	C57BL/6 (B6) mice, Lung cancer, Breast cancer	[63,65,66,67,68]
Hypoxic Immunosuppression	Production of immunosuppressive macrophages, Granzyme B, CCL20 and CXCL5, hypoxia-induced programs	TADCs, pDCs, tolorigenic DCs	Sarcoma, HCC, TNBC	[72,74,75,76,77]
Clinical Trials	Stage I clinical pilot trials, stage II clinical trial, stage III clinical trial	mRNA-loaded DCs, (hTERT)-expressing autologous DCs, WT1 mRNA-DCs, autologous DCs	Glioblastoma, AML, Breast cancer, Pancreatic cancer, Melanoma	[82,83,84,85,86,87,88,89,90]